Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Where is ovarian cancer treatment headed?

Domenica Lorusso • 29 Nov 2018
ESMO 2018
Gynecological Cancer Ovarian Cancer Olaparib
SOLO-1

The landscape of ovarian cancer treatment is rapidly changing, with PARP inhibitors moving into the first-line setting and new research addressing homologous recombination deficiency-positive patients. Concurrently, translational medicine seeks to optimize treatment strategies by comparing combination therapies and immunotherapies, says Domenica Lorusso, MD, PhD, of the IRCCS National Cancer Institute, Milan, Italy. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Domenica Lorusso

0:47
Assessing chemotherapy and immunotherapy in dMMR endometrial cancer
Domenica Lorusso • 23 Oct 2023
0:39
ESMO 2023 highlights: KEYNOTE-A18 and more
Domenica Lorusso • 23 Oct 2023
0:52
The importance of HRD testing in ovarian cancer
Domenica Lorusso • 23 Oct 2023
1:14
KEYNOTE-A18: pembrolizumab with chemoradiotherapy for advanced cervical cancer
Domenica Lorusso • 23 Oct 2023

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals